Qualigen Therapeutics shareholders approved a strategic transformation, with Faraday Future becoming the majority shareholder. The company will rebrand as AIxCrypto Holdings, transitioning from biotechnology to a Web3-driven decentralized AI technology platform, with a new ticker symbol AIXC.

Faraday Future reported Q3 2025 financial results, highlighting progress on the FX Super One electric vehicle, securing pre-orders, entering pre-production, and gaining access to Tesla's Supercharger network. The company experienced a $206.8 million operational loss but secured $136 million in financing commitments.

Faraday Future plans to enter pilot build and production phase for FX Super One, with first parts shipment scheduled for November 15, 2025. The company filed a blockchain-based car sharing patent and is preparing to release Q3 2025 financial results.

Faraday Future announced strategic advisor Chris Nixon Cox, received B2B preorders for over 200 FX Super One units, and noted Vanguard increased its share holdings by 36% in Q3.

Qualigen Therapeutics plans to rebrand as AIxCrypto on November 12, 2025, focusing on Web3 and crypto asset initiatives, including launching a DeAI trading platform and expanding its crypto treasury.